21 CFR Part 1271 · Human Cells, Tissues, and Cellular and Tissue-Based Products

§ 1271.195 Environmental control and monitoring

Subpart D - Current Good Tissue Practice Official text on eCFR Amendment history

(a) Environmental control. Where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT/Ps or equipment, or accidental exposure of HCT/Ps to communicable disease agents, you must adequately control environmental conditions and provide proper conditions for operations. Where appropriate, you must provide for the following control activities or systems:

(1) Temperature and humidity controls;

(2) Ventilation and air filtration;

(3) Cleaning and disinfecting of rooms and equipment to ensure aseptic processing operations; and

(4) Maintenance of equipment used to control conditions necessary for aseptic processing operations.

(b) Inspections. You must inspect each environmental control system periodically to verify that the system, including necessary equipment, is adequate and functioning properly. You must take appropriate corrective action as necessary.

(c) Environmental monitoring. You must monitor environmental conditions where environmental conditions could reasonably be expected to cause contamination or cross-contamination of HCT/Ps or equipment, or accidental exposure of HCT/Ps to communicable disease agents. Where appropriate, you must provide environmental monitoring for microorganisms.

(d) Records. You must document, and maintain records of, environmental control and monitoring activities.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 1271.195

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Human Tissue for Transplantation).

  • Monitoring--cross contamination, exposure to CD 25
  • Documentation not maintained 21
  • Adequate control, proper conditions 20
  • Aseptic processing---cleaning, disinfecting 19
  • Monitoring-microorganisms where appropriate 17
  • Corrective actions 10

Warning letters citing § 1271.195

3 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 1271.195

Amendment history

Federal Register documents that created or amended this section.